Business Context and Reporting Period
Company: Acacia Research Corporation (California Corporation)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 1995
Business Model: The Company engages in business development (sponsoring start-ups) and capital management. It is no longer considered a development stage company following significant revenue from the sale of its initial business development investment, Whitewing Labs. Operations are primarily driven by Whitewing Labs (health care products) and business development investment sales.
Key Financial Metrics
| Metric | Nine Months Ended Sept 30, 1995 | Nine Months Ended Sept 30, 1994 | Three Months Ended Sept 30, 1995 | Three Months Ended Sept 30, 1994 |
|---|---|---|---|---|
| Total Sales | $3,756,833 | $174,088 | $1,891,292 | $87,902 |
| Gross Profit | $3,429,424 | $144,134 | $1,734,299 | $67,448 |
| Net Income (Loss) | $603,907 | ($769,665) | $486,701 | ($325,245) |
| Earnings Per Share (Diluted) | $0.24 | ($0.34) | $0.19 | ($0.15) |
| Cash and Equivalents (Ending) | $3,039,628 | $889,348 | $3,039,628 | $889,348 |
| Total Assets | $5,554,066 | $1,240,836 | $5,554,066 | $1,240,836 |
| Total Liabilities | $2,162,510 | $294,623 | $2,162,510 | $294,623 |
| Line of Credit Outstanding | $2,000,000 | $0 | $2,000,000 | $0 |
Margin Analysis: Gross margin for the nine months ended Sept 30, 1995, was approximately 91.3%, significantly higher than the 82.8% in the prior year period, driven by high-margin business development investment sales.
Material Changes vs. Prior Period
- Profitability Turnaround: The Company achieved its third consecutive profitable quarter, reporting net income of $486,701 for Q3 1995 compared to a net loss of $325,245 in Q3 1994. For the nine-month period, the Company swung from a loss of $769,665 to income of $603,907.
- Revenue Composition: Total sales increased dramatically due to two factors:
- Whitewing Labs Sales: Increased from $87,902 (Q3 1994) to $1,104,292 (Q3 1995) due to expanded direct response mailings and magazine advertising.
- Investment Sales: The Company sold a portion of its interest in a subsidiary (Whitewing Labs) in Q3 1995, generating $787,000 in sales revenue and a gain of $787,000.
- Liquidity and Debt: Cash and cash equivalents increased from $1,000,389 (Dec 31, 1994) to $3,039,628 (Sept 30, 1995). This was funded by a new $2,000,000 line of credit, proceeds from common stock issuance ($886,572), and minority interest proceeds ($1,035,570). A $200,000 convertible note payable outstanding in 1994 was redeemed in Q2 1995.
- Investments: The Company invested $600,000 in Acacia Capital Partners, L.P. during the period.
Guidance, Outlook, and Risks
- Outlook: Management expects management fees from Acacia Capital Partners, L.P. to increase significantly in 1996. A companion offshore private investment fund for European investors is planned for January 1996. Two high-tech businesses are in development, with at least one expected to generate revenue in 1996. Whitewing Labs has filed an SEC registration statement for a public offering expected by year-end.
- Capital Requirements: Management believes that unless $25,000,000 is invested in Acacia Capital Partners, L.P., management fees will be insufficient to sustain planned operations. The Company may need to rely on additional common stock sales or new business development.
- Risks and Contingencies:
- Litigation: Whitewing Labs is named in pending litigation regarding copyright, trademark infringement, and false representations. Counsel believes claims are without merit and covered by insurance.
- Concentration: All operating revenues are currently derived from Whitewing Labs and business development investments; investment management services have not yet generated significant revenue.
- Restricted Cash: Whitewing Labs must maintain a reserve cash account equal to 5% of the preceding six months' gross credit card sales (or $5,000). As of Sept 30, 1995, $38,417 was restricted.
Investor Verification Checklist
- Sustainability of Revenue: Verify if the $787,000 gain from the sale of Whitewing Labs equity is a one-time event or indicative of a recurring business model.
- Capital Raise Success: Monitor the ability of Acacia Capital Partners, L.P. to raise the targeted $25,000,000 to ensure management fee sufficiency.
- Whitewing Labs IPO: Confirm the status of Whitewing Labs' public offering and its impact on the Company's minority interest and future revenue streams.
- Debt Covenants: Review the terms of the $2,000,000 line of credit (collateralized by money market accounts) and the $1,055,000 in notes receivable from stockholders to assess liquidity risks.
- Litigation Outcome: Track the resolution of the pending litigation against Whitewing Labs to ensure no material financial impact.